RTTNews | Dec 29, 2020 06:44AM EST

06:43 Tuesday, December 29, 2020 (RTTNews.com) - MediciNova Inc. (MNOV) said Tuesday that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive multiple sclerosis.

The patent maturing from the allowed patent application is expected to expire no earlier than October 2039.

The allowed claims cover a method of (i) alleviating the negative effects of progressive multiple sclerosis, treating progressive multiple sclerosis, or slowing the progression of progressive multiple sclerosis by administering MN-166 (ibudilast) and interferon-beta in separate dosage forms.

Read the original article on RTTNews ( https://www.rttnews.com/3156525/medicinova-receives-new-patent-covering-mn-166-for-treatment-of-progressive-multiple-sclerosis.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved